|Systematic (IUPAC) name|
|Molar mass||359.47 g/mol|
Lavoltidine (INN, USAN, BAN; previously known as loxtidine, code name AH-23,844) is a highly potent and selective H2 receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline) as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.
- "WHO Drug Information. Vol 4, No. 3, 1990. International Nonproprietary Names for Pharmaceutical Substances. Recommended International Nonproprietary Names (Rec. INN): List 30" (PDF). World Health Organization. p. 7. Retrieved 12 January 2016.
- "Drug Profile: Lavoltidine". AdisInsight. Springer International Publishing AG. Retrieved 12 January 2016.
- Washington, Neena (1991). Antacids and anti-reflux agents. Boca Raton: CRC Press. ISBN 0-8493-5444-7.
- Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN 0-412-54090-8.